LONDON--(BUSINESS WIRE)--As no effective vaccine against the hepatitis C virus (HCV) has been discovered so far, the market is driven by therapeutics. Additionally, an increased awareness of the disease and China’s tendency to treat HCV once it is diagnosed are anticipated to be the key drivers of market growth during the forecast period.
Standard interferon drugs are currently leading the market in China. Merck’s Intron A (interferon alfa-2b) is the most typically prescribed standard interferon in the country, though Roferon-A (interferon alfa-2a) and Kadmon’s Infergen (interferon alfacon-1) are used often as well. The entrance of next-generation HCV therapies is expected to radically alter the HCV treatment algorithm. Interferon-free regimens are likely to become increasingly popular due to their more tolerable side-effect profiles and decreased duration of therapy as against the current standard of medical care.
Topical research report “PharmaPoint: Hepatitis C Virus - China Drug Forecast and Market Analysis” created by GlobalData provides an all-encompassing analysis of the HCV market in China.
The study gives a detailed overview of the disease including epidemiology, etiology and symptoms; offers diagnosis, pathology and treatment guidelines; and examines the changing competitive landscape for HCV. The report presents insightful information on the key drugs in the country including product description, safety and efficacy profiles and a SWOT analysis; offers sales forecast for the top drugs in China from 2012-2022. In-depth analysis of the impact of major events as well as of the key drivers and restraints affecting the HCV market is included, too.
Report Details:
Title: PharmaPoint: Hepatitis C Virus - China Drug Forecast and Market Analysis
Published: May, 2013
Pages: 102
Price: US$ 4,995.00
More Topical GlobalData Reports Include:
- PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis
- PharmaPoint: Hepatitis C Virus - Italy Drug Forecast and Market Analysis
- PharmaPoint: Hepatitis C Virus - Japan Drug Forecast and Market Analysis
- PharmaPoint: Hepatitis C Virus - Spain Drug Forecast and Market Analysis
- PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis
More topical reports by GlobalData can be found at http://marketpublishers.com/members/global_data/info.html
